Crestor RUSH (The Efficacy of RosUvaStatin for Korean Dyslipidemia Patients With Hypertension ) - Full Text View

Crestor RUSH (The Efficacy of RosUvaStatin for Korean Dyslipidemia Patients With Hypertension )

This study has been completed.

Sponsored by:	AstraZeneca
Information provided by:	AstraZeneca
ClinicalTrials.gov Identifier:	NCT00526708

Purpose

To evaluate the efficacy of rosuvastatin in Korean dyslipidemia patients with hypertension.

Condition

Dyslipidemia
Hypertension

MedlinePlus related topics:

High Blood Pressure

ChemIDplus related topics:

Rosuvastatin Rosuvastatin calcium

U.S. FDA Resources

Study Type:	Observational
Study Design:	Prospective

Official Title:	RUSH (Evaluating the Efficacy of RosUvaStatin for Korean Dyslipidemia Patients With Hypertension in Real World Practice)

Further study details as provided by AstraZeneca:

Estimated Enrollment:	5000
Study Start Date:	June 2007
Study Completion Date:	November 2007
Primary Completion Date:	August 2007 (Final data collection date for primary outcome measure)

Eligibility

Ages Eligible for Study:	18 Years and older
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	Yes

Criteria

Inclusion Criteria:

Hyperlipidemia patients who are prescribed with rosuvastatin 10mg, based on clinical grounds and fulfil the following criteria
1. Over 18 years of age
2. Currently or previously diagnosed with hypertension and receiving medical care

Exclusion Criteria:

Patients already taking other hyperlipidemic agents
Patients who do not fulfil the indication criteria for statin therapy
Patients who do not have baseline and/or follow-up lipid data to verify the efficacy data

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00526708

Locations


Korea, Republic of, Jongro-gu
	Research Site
	Seoul, Jongro-gu, Korea, Republic of

Korea, Republic of, Kangnam-gu
	Research Site
	Seoul, Kangnam-gu, Korea, Republic of

Korea, Republic of, Songpa-gu
	Research Site
	Seoul, Songpa-gu, Korea, Republic of

Sponsors and Collaborators

AstraZeneca

Investigators


Study Director:	Hyunah Caroline Choi	AstraZeneca Korea

More Information

Related Info This link exits the ClinicalTrials.gov site

Study ID Numbers:	NIS-CKR-CRE-2007/7
First Received:	September 5, 2007
Last Updated:	October 14, 2008
ClinicalTrials.gov Identifier:	NCT00526708
Health Authority:	Korea: Food and Drug Administration

Keywords provided by AstraZeneca:

dyslipidemia

hypertension

rosuvastatin

efficacy

Naturalistic

Observational

Study placed in the following topic categories:

Rosuvastatin

Metabolic Diseases

Vascular Diseases

Metabolic disorder

Dyslipidemias

Lipid Metabolism Disorders

Hypertension

Additional relevant MeSH terms:

Antimetabolites

Molecular Mechanisms of Pharmacological Action

Therapeutic Uses

Antilipemic Agents

Enzyme Inhibitors

Cardiovascular Diseases

Anticholesteremic Agents

Hydroxymethylglutaryl-CoA Reductase Inhibitors

Pharmacologic Actions

ClinicalTrials.gov processed this record on October 16, 2008